13 research outputs found

    Case Reports1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility

    Get PDF
    Background: Thoracic aortic aneurysms (TAA) and dissections are not uncommon causes of sudden death in young adults. Loeys-Dietz syndrome (LDS) is a rare, recently described, autosomal dominant, connective tissue disease characterized by aggressive arterial aneurysms, resulting from mutations in the transforming growth factor beta (TGFβ) receptor genes TGFBR1 and TGFBR2. Mean age at death is 26.1 years, most often due to aortic dissection. We report an unusually late presentation of LDS, diagnosed following elective surgery in a female with a long history of joint hypermobility. Methods: A 51-year-old Caucasian lady complained of chest pain and headache following a dural leak from spinal anaesthesia for an elective ankle arthroscopy. CT scan and echocardiography demonstrated a dilated aortic root and significant aortic regurgitation. MRA demonstrated aortic tortuosity, an infrarenal aortic aneurysm and aneurysms in the left renal and right internal mammary arteries. She underwent aortic root repair and aortic valve replacement. She had a background of long-standing joint pains secondary to hypermobility, easy bruising, unusual fracture susceptibility and mild bronchiectasis. She had one healthy child age 32, after which she suffered a uterine prolapse. Examination revealed mild Marfanoid features. Uvula, skin and ophthalmological examination was normal. Results: Fibrillin-1 testing for Marfan syndrome (MFS) was negative. Detection of a c.1270G > C (p.Gly424Arg) TGFBR2 mutation confirmed the diagnosis of LDS. Losartan was started for vascular protection. Conclusions: LDS is a severe inherited vasculopathy that usually presents in childhood. It is characterized by aortic root dilatation and ascending aneurysms. There is a higher risk of aortic dissection compared with MFS. Clinical features overlap with MFS and Ehlers Danlos syndrome Type IV, but differentiating dysmorphogenic features include ocular hypertelorism, bifid uvula and cleft palate. Echocardiography and MRA or CT scanning from head to pelvis is recommended to establish the extent of vascular involvement. Management involves early surgical intervention, including early valve-sparing aortic root replacement, genetic counselling and close monitoring in pregnancy. Despite being caused by loss of function mutations in either TGFβ receptor, paradoxical activation of TGFβ signalling is seen, suggesting that TGFβ antagonism may confer disease modifying effects similar to those observed in MFS. TGFβ antagonism can be achieved with angiotensin antagonists, such as Losartan, which is able to delay aortic aneurysm development in preclinical models and in patients with MFS. Our case emphasizes the importance of timely recognition of vasculopathy syndromes in patients with hypermobility and the need for early surgical intervention. It also highlights their heterogeneity and the potential for late presentation. Disclosures: The authors have declared no conflicts of interes

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

    SAMI3 data in netCDF format (2019-Mar-31)

    No full text
    SAMI3 (Sami3 is Also a Model of the Ionosphere) is a seamless, three-dimensional, physics-based model of the ionosphere (Huba et al, 2008). It is based on SAMI2, a two-dimensional model of the ionosphere (Huba et al., 2000). SAMI3 models the plasma and chemical evolution of seven ion species (H⁺, He⁺, N⁺, O⁺, N⁺₂, NO⁺ and O⁺₂). The temperature equation is solved for three ion species (H⁺, He⁺ and O⁺) and for the electrons. Ion inertia is included in the ion momentum equation for motion along the geomagnetic field. This is important in modeling the topside ionosphere and plasmasphere where the plasma becomes collisionless. SAMI3 includes 21 chemical reactions and radiative recombination, and uses a nonorthogonal, nonuniform, fixed grid for the magnetic latitude range +/- 89 degrees.. Drivers Neutral composition, temperature, and winds: NRLMSISE00 (Picone et al., 2002) and HWM14 (Drob et al., 2015). Solar radiation: Flare Irradiance Spectral Model version 2 (FISM v2) Magnetic field: Richmond apex model [Richmond, 1995]. Neutral wind dynamo electric field: Determined from the solution of a 2D potential equation [Huba et at., 2008]. For the SAMI3/Weimer configuration: High latitude electric field: calculated from the empirical Weimer model for the potential. For the SAMI3/AMPERE configuration: High latitude electric field: calculated using the Magnetosphere-Ionosphere Coupling solver (MIX) developed by Merkin and Lyon (2010). The inputs to MIX are SAMI3's internal conductances, plus field-aligned current observations from Active Magnetosphere and Planetary Electrodynamics Response Experiment (AMPERE), derived from the 66+ satellite Iridium NEXT constellation's engineering magnetometer data. This potential calculation is described in Chartier et al (2022). For ease of use, SAMI3 output is remapped to a regular grid using the Earth System Modeling Framework by Hill et al (2004

    SAMI3 data in netCDF format (2019-Mar-30)

    No full text
    SAMI3 (Sami3 is Also a Model of the Ionosphere) is a seamless, three-dimensional, physics-based model of the ionosphere (Huba et al, 2008). It is based on SAMI2, a two-dimensional model of the ionosphere (Huba et al., 2000). SAMI3 models the plasma and chemical evolution of seven ion species (H⁺, He⁺, N⁺, O⁺, N⁺₂, NO⁺ and O⁺₂). The temperature equation is solved for three ion species (H⁺, He⁺ and O⁺) and for the electrons. Ion inertia is included in the ion momentum equation for motion along the geomagnetic field. This is important in modeling the topside ionosphere and plasmasphere where the plasma becomes collisionless. SAMI3 includes 21 chemical reactions and radiative recombination, and uses a nonorthogonal, nonuniform, fixed grid for the magnetic latitude range +/- 89 degrees.. Drivers Neutral composition, temperature, and winds: NRLMSISE00 (Picone et al., 2002) and HWM14 (Drob et al., 2015). Solar radiation: Flare Irradiance Spectral Model version 2 (FISM v2) Magnetic field: Richmond apex model [Richmond, 1995]. Neutral wind dynamo electric field: Determined from the solution of a 2D potential equation [Huba et at., 2008]. For the SAMI3/Weimer configuration: High latitude electric field: calculated from the empirical Weimer model for the potential. For the SAMI3/AMPERE configuration: High latitude electric field: calculated using the Magnetosphere-Ionosphere Coupling solver (MIX) developed by Merkin and Lyon (2010). The inputs to MIX are SAMI3's internal conductances, plus field-aligned current observations from Active Magnetosphere and Planetary Electrodynamics Response Experiment (AMPERE), derived from the 66+ satellite Iridium NEXT constellation's engineering magnetometer data. This potential calculation is described in Chartier et al (2022). For ease of use, SAMI3 output is remapped to a regular grid using the Earth System Modeling Framework by Hill et al (2004

    Generalizable spelling using a speech neuroprosthesis in an individual with severe limb and vocal paralysis

    No full text
    Neuroprostheses have the potential to restore communication to people who cannot speak or type due to paralysis. However, it is unclear if silent attempts to speak can be used to control a communication neuroprosthesis. Here, we translated direct cortical signals in a clinical-trial participant (ClinicalTrials.gov; NCT03698149) with severe limb and vocal-tract paralysis into single letters to spell out full sentences in real time. We used deep-learning and language-modeling techniques to decode letter sequences as the participant attempted to silently spell using code words that represented the 26 English letters (e.g. "alpha" for "a"). We leveraged broad electrode coverage beyond speech-motor cortex to include supplemental control signals from hand cortex and complementary information from low- and high-frequency signal components to improve decoding accuracy. We decoded sentences using words from a 1,152-word vocabulary at a median character error rate of 6.13% and speed of 29.4 characters per minute. In offline simulations, we showed that our approach generalized to large vocabularies containing over 9,000 words (median character error rate of 8.23%). These results illustrate the clinical viability of a silently controlled speech neuroprosthesis to generate sentences from a large vocabulary through a spelling-based approach, complementing previous demonstrations of direct full-word decoding
    corecore